Nothing Special   »   [go: up one dir, main page]

DE69636538D1 - Antagoniste von interleukin-15 - Google Patents

Antagoniste von interleukin-15

Info

Publication number
DE69636538D1
DE69636538D1 DE69636538T DE69636538T DE69636538D1 DE 69636538 D1 DE69636538 D1 DE 69636538D1 DE 69636538 T DE69636538 T DE 69636538T DE 69636538 T DE69636538 T DE 69636538T DE 69636538 D1 DE69636538 D1 DE 69636538D1
Authority
DE
Germany
Prior art keywords
disclosed
interleukin
antagonist
transducing
subunits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636538T
Other languages
English (en)
Other versions
DE69636538T2 (de
DE69636538T3 (de
Inventor
H Grabstein
K Pettit
J Paxton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23550114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69636538(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE69636538D1 publication Critical patent/DE69636538D1/de
Publication of DE69636538T2 publication Critical patent/DE69636538T2/de
Application granted granted Critical
Publication of DE69636538T3 publication Critical patent/DE69636538T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
DE69636538T 1995-02-22 1996-02-21 Antagoniste von interleukin-15 Expired - Lifetime DE69636538T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/392,317 US5795966A (en) 1995-02-22 1995-02-22 Antagonists of interleukin-15
US392317 1995-02-22
PCT/US1996/002520 WO1996026274A1 (en) 1995-02-22 1996-02-21 Antagonists of interleukin-15

Publications (3)

Publication Number Publication Date
DE69636538D1 true DE69636538D1 (de) 2006-10-26
DE69636538T2 DE69636538T2 (de) 2007-05-16
DE69636538T3 DE69636538T3 (de) 2010-10-28

Family

ID=23550114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636538T Expired - Lifetime DE69636538T3 (de) 1995-02-22 1996-02-21 Antagoniste von interleukin-15

Country Status (16)

Country Link
US (5) US5795966A (de)
EP (2) EP0811065B2 (de)
JP (2) JPH11500908A (de)
KR (1) KR19980702238A (de)
AT (1) ATE339505T1 (de)
AU (1) AU708549B2 (de)
CA (2) CA2210491C (de)
DE (1) DE69636538T3 (de)
DK (1) DK0811065T4 (de)
ES (1) ES2271951T5 (de)
FI (2) FI120497B (de)
MX (1) MX9706294A (de)
NO (2) NO321990B1 (de)
NZ (1) NZ303843A (de)
PT (1) PT811065E (de)
WO (1) WO1996026274A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192935B1 (en) 1993-03-08 2007-03-20 Amgen Inc. Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
AU680909B2 (en) * 1994-04-06 1997-08-14 Immunex Corporation Interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
AUPN378095A0 (en) * 1995-06-23 1995-07-20 Bresagen Limited Haemopoietic growth factor antagonists and uses therefor
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP0927254B1 (de) * 1996-04-26 2005-06-22 Beth Israel Deaconess Medical Center, Inc. Interleukin-15 antagoniste
DK0927254T3 (da) * 1996-04-26 2005-10-03 Beth Israel Hospital Interleukin-15-antagonister
CA2269060C (en) 1996-10-17 2009-04-07 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
US5874566A (en) * 1996-10-25 1999-02-23 Hisamitsu Pharmaceutical Co. Inc. Il-15 triplex oligonucleotides
DE69810091T2 (de) * 1997-02-21 2003-10-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde Verwendung von interleukin-15
WO2000001851A1 (en) * 1998-07-07 2000-01-13 Hisamitsu Pharmaceutical Co., Inc. Antisense oligonucleotides targeted to il-15
GB9814892D0 (en) * 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1165791B1 (de) * 1999-03-09 2007-10-31 ZymoGenetics, Inc. Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
WO2001002003A1 (en) * 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
EP1226173A1 (de) * 1999-10-07 2002-07-31 Maxygen Aps Einzelkettige antagonistische polypeptide
RU2270691C2 (ru) 2000-05-12 2006-02-27 Бет Израел Диконесс Медикал Сентер, Инк. Композиции и способы достижения иммунной супрессии
IL154925A0 (en) 2000-09-14 2003-10-31 Beth Israel Hospital Modulation of il-2 and il-15-mediated t cell responses
AU2002320630A1 (en) 2001-07-17 2003-03-03 University Of Florida Detecting and treating reproductive tract disorders
ATE531390T1 (de) 2001-08-23 2011-11-15 Genmab As Interleukin-15-(il-15-)spezifische menschliche antikörper
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
JP4547158B2 (ja) * 2002-04-15 2010-09-22 株式会社エヌ・ティ・ティ・ドコモ バイリニアマッピングを使用する署名スキーム
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
CN1780856A (zh) * 2003-02-26 2006-05-31 根马布股份公司 白介素15(il－15)的特异性人抗体
ATE460451T1 (de) * 2003-07-22 2010-03-15 Nektar Therapeutics Verfahren zur herstellung von funktionalisierten polymeren aus polymeralkoholen
US7858081B2 (en) * 2004-02-27 2010-12-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutants having agonists/antagonists activity
TW200613552A (en) * 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
US20060104945A1 (en) * 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (de) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
US8055951B2 (en) * 2007-04-10 2011-11-08 International Business Machines Corporation System, method and computer program product for evaluating a virtual machine
ES2518393T3 (es) 2007-05-11 2014-11-05 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
CU23716A1 (es) * 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
US20100145285A1 (en) * 2008-12-09 2010-06-10 Cook Critical Care, Incorporated Multi-lumen catheter configuration
US9487800B2 (en) * 2010-09-08 2016-11-08 Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
ES2579077T3 (es) 2010-09-21 2016-08-04 Altor Bioscience Corporation Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
AU2012207456C1 (en) 2011-01-18 2017-05-04 Bioniz Therapeutics, Inc. Compositions and methods for modulating gamma-c-cytokine activity
HUE058364T2 (hu) 2013-04-19 2022-07-28 Cytune Pharma Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2016004060A2 (en) 2014-06-30 2016-01-07 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US10333696B2 (en) 2015-01-12 2019-06-25 X-Prime, Inc. Systems and methods for implementing an efficient, scalable homomorphic transformation of encrypted data with minimal data expansion and improved processing efficiency
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
JP7183042B2 (ja) * 2016-01-07 2022-12-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の免疫炎症性疾患のための治療法
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
CN118562016A (zh) 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
WO2018119246A1 (en) * 2016-12-21 2018-06-28 Cephalon, Inc. Antibodies that specifically bind to human il-15 and uses thereof
CU24546B1 (es) 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
MX2019013621A (es) 2017-05-15 2020-01-13 Nektar Therapeutics Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CU24545B1 (es) 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
EP0276846A3 (de) 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0627932B1 (de) 1992-11-04 2002-05-08 City Of Hope Antikörperkonstrukte
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5552303A (en) * 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
EP0822830B1 (de) † 1995-04-27 2008-04-02 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
WO1996034096A1 (en) † 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Also Published As

Publication number Publication date
MX9706294A (es) 1997-10-31
US6165466A (en) 2000-12-26
EP0811065A1 (de) 1997-12-10
AU708549B2 (en) 1999-08-05
ATE339505T1 (de) 2006-10-15
EP0811065B1 (de) 2006-09-13
EP0811065B2 (de) 2010-06-30
FI120497B (fi) 2009-11-13
JPH11500908A (ja) 1999-01-26
AU5027596A (en) 1996-09-11
NO973705D0 (no) 1997-08-12
CA2637795C (en) 2011-01-18
DK0811065T3 (da) 2006-11-20
FI121571B (fi) 2011-01-14
JP2008133276A (ja) 2008-06-12
PT811065E (pt) 2007-01-31
FI973361A0 (fi) 1997-08-15
CA2210491C (en) 2008-11-18
NO20060194L (no) 1997-10-22
ES2271951T5 (es) 2010-11-29
ES2271951T3 (es) 2007-04-16
CA2210491A1 (en) 1996-08-29
FI20060080A (fi) 2006-01-27
CA2637795A1 (en) 1996-08-29
FI973361A (fi) 1997-10-15
EP1770163A3 (de) 2008-10-22
NO321990B1 (no) 2006-07-31
US6177079B1 (en) 2001-01-23
US6013480A (en) 2000-01-11
EP1770163A2 (de) 2007-04-04
NZ303843A (en) 1999-04-29
DE69636538T2 (de) 2007-05-16
NO973705L (no) 1997-10-22
US5795966A (en) 1998-08-18
KR19980702238A (ko) 1998-07-15
WO1996026274A1 (en) 1996-08-29
DK0811065T4 (da) 2010-08-23
US6168783B1 (en) 2001-01-02
DE69636538T3 (de) 2010-10-28

Similar Documents

Publication Publication Date Title
DE69636538D1 (de) Antagoniste von interleukin-15
ATE74126T1 (de) D-prostaglandine und ihre anwendung in tranquilizern und hypnotikum.
EP0430385A3 (en) Substituted 1,2,4-triazolo-(4,3-a)pyridines, and substituted n'-(2-pyridyl)-hydrazones, and their use as herbicides
FI935585A0 (fi) Pyrrolopyrimidiner
ES2175066T3 (es) Antagonistas triciclicos de la vasopresina.
NO911749D0 (no) Bis-arylamid og urea-antagonister for blodplateaktiverende faktor.
ITGE910067A0 (it) Dispositivo per l'agugliatura di falde d'ovatta
FI882737A (fi) Foerfarande foer framstaellning av n-(aryl-, aryloxi-, aryltio-arylsulfinyl och -arylsulfonyl)-alkyl-n,n'- (eller n'n')-alkylamino-alkyl-urea och -cyanoguanidin.
DE68921127D1 (de) Schienenwagen und dessen Konstruktionsverfahren.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ATE123942T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
KR900700136A (ko) 특정 paf 길항제/항히스타민제 조성물
DE69024871D1 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
DK0745072T3 (da) 4-aminoderivater af 5-substitueret mycophenolsyre
FI892257A (fi) Anordning foer infoerande, pressning och uttagning av ett skiktpaket i resp. ur en varmpress.
DE68926899D1 (de) Hybride monoklonale Antikörper, ihre Herstellung und Verwendung
DE59005647D1 (de) Verwendung von polyglykolethergemischen als antischaummittel.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
FR2666834B1 (fr) Infrastructure pour construction anti-sismique et anticyclonique.
DE3481403D1 (de) Verwendung von "nafazatrom".
DE59102319D1 (de) N-Aryltetrahydrophthalimide und ihre Verwendung als Herbizide.
BLACKSTOCK Nonlinear Acoustics Research(Final Report, 1 Aug. 1984- 31 Dec. 1995)
ATE135572T1 (de) Verwendung von 1,2,4-trioxanen als anti- parasitika und anthelmintika
ES1011438Y (es) Nuevo juego infantil.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUSSER,

8366 Restricted maintained after opposition proceedings